Dr. Shiri Shulman from Assuta discusses the importance of continuity in treatment during wartime and innovative therapies ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

The medication, Eylea 8mg, for the treatment of wet age-related macular degeneration (AMD) was administered by ...

Age-related macular ... Wet AMD, though less common, is more severe and responsible for most cases of advanced vision loss. In wet AMD, abnormal blood vessels grow under the retina and leak blood or ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

ROCKVILLE, MD, USA I October 21, 2024 I REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the ...